Roger F Butterworth
Overview
Explore the profile of Roger F Butterworth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
121
Citations
2784
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Butterworth R
Front Neurosci
. 2023 Mar;
17:1128157.
PMID: 36968489
Advent of the acute respiratory coronavirus SARS-CoV-2 has resulted in the search for novel antiviral agents and in the repurposing of existing agents with demonstrated efficacy against other known coronaviruses...
2.
Butterworth R
Drugs R D
. 2021 Jun;
21(3):267-272.
PMID: 34152583
Several adamantanes have established actions against coronaviruses. Amantadine, rimantadine, bananins and the structurally related memantine are effective against human respiratory coronavirus HCoV-OC43, bovine coronavirus and severe acute respiratory syndrome coronavirus...
3.
Butterworth R
Drugs R D
. 2021 Apr;
21(2):123-132.
PMID: 33890246
Effective lowering of circulating ammonia is the mainstay strategy in the prevention and treatment of hepatic encephalopathy in cirrhosis and there is increasing interest in agents with the metabolic potential...
4.
Hazell A, Butterworth R
Metab Brain Dis
. 2020 Nov;
36(2):239-246.
PMID: 33245475
Thiamine deficiency (TD) results in focal lesions in several regions of the rat brain including the thalamus and inferior colliculus. Since alterations in blood-brain barrier (BBB) integrity may play a...
5.
Butterworth R
Alcohol Health Res World
. 2019 Dec;
19(2):122-129.
PMID: 31798087
Chronic severe liver disease (i.e., cirrhosis) is a common complication of chronic alcohol abuse. Cirrhosis can cause brain dysfunction, most notably the disorder portal-systemic encephalopathy (PSE), which is characterized by...
6.
Butterworth R
Metab Brain Dis
. 2019 Jul;
35(1):75-81.
PMID: 31338724
The present systematic review with meta-analysis was undertaken to review the evidence base in support of a beneficial effect of L-ornithine L-aspartate (LOLA) for the prevention/prophylaxis of overt hepatic encephalopathy...
7.
Butterworth R
Can J Gastroenterol Hepatol
. 2019 Jun;
2019:8182195.
PMID: 31183339
Sarcopenia is a common complication of cirrhosis with a negative impact on posttransplant outcome, health-related quality of life (HRQOL), and patient survival. Studies in experimental animals and in patients demonstrate...
8.
Butterworth R, McPhail M
Drugs
. 2019 Feb;
79(Suppl 1):31-37.
PMID: 30706425
This manuscript represents an appraisal of the evidence in support of L-ornithine-L-aspartate (LOLA) for the management and treatment of hepatic encephalopathy (HE) in cirrhosis. Meta-analyses of randomized controlled trials (RCTs)...
9.
Butterworth R
Drugs
. 2019 Feb;
79(Suppl 1):17-21.
PMID: 30706423
Neuropathology of hepatic encephalopathy (HE) in cirrhosis is primarily astroglial in nature characterized by Alzheimer type 2 astrocytosis together with activation of microglia indicative of neuroinflammation. Focal loss of neurons...
10.